Which generation of targeted drug is Mobotinib? How should it be taken correctly?

Mobotinib, also known as moboxetinib, is a targeted drug that has attracted much attention in the field of lung cancer treatment. So, which generation of targeted drugs does it belong to? In fact, Mobotinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), specifically designed for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations. The particularity of this mutation makes it difficult for traditional treatments to be effective, and the emergence of mobotinib undoubtedly brings new treatment options to these patients.

As a third-generation EGFR inhibitorMobotinib has significantly improved selectivity and inhibitory effect compared with the previous two generations of drugs. It can block abnormal signaling caused by EGFR exon 20 insertion mutations more accurately and effectively, thereby promoting tumor cell apoptosis, stopping growth, and effectively inhibiting tumor development. This feature allowed mobotinib to demonstrate impressive efficacy and tolerability in clinical trials.

So, how should patients take mobotinib correctly? First of all, medical advice must be strictly followed. The recommended daily dose is 160 mg once a day, administered orally. Patients can choose to take it on an empty stomach or after meals, but in order to maintain stable blood concentration, it is recommended to take it at the same time every day. Additionally, capsules should be swallowed whole and the contents should not be opened, chewed, or dissolved. If you miss a dose and it has been more than 6 hours, you do not need to take it again. Just take the next dose at your regular time the next day. If vomiting occurs after taking it, there is no need to take it again. Take the next dose at the prescribed time the next day.

Patients also need to pay close attention to their body's reaction while taking mobotinib. Although Mobotinib is highly effective, it may be accompanied by some side effects, such as diarrhea, rash, nausea, oral inflammation, vomiting, loss of appetite, paronychia, fatigue, dry skin, and musculoskeletal pain. The severity of these side effects varies from person to person. Once serious adverse reactions occur, patients should seek medical advice immediately and consult a doctor, and adjust the dosage or take other treatment measures according to the doctor's advice.

At the same time, patients should also be careful to avoid concurrent use with drugs that may interact while taking mobotinib. For example, grapefruit and its products may interact with mobotinib, increasing the risk of side effects and should be avoided.

In summary, as a third-generation EGFR inhibitor, mobotinib provides a new treatment option for NSCLC patients carrying EGFR exon 20 insertion mutations. When taking Mobotinib, patients must strictly follow the doctor's instructions, take it correctly, and closely monitor the body's reaction to ensure the efficacy and safety of the drug. At the same time, avoiding simultaneous use with drugs that may interact is an important step in ensuring the therapeutic effect.

References:

https://www.drugs.com/search.php?searchterm=Exkivity&sources%5B%5D=professional